KR20210032280A - 약학적 조성물의 제조 방법 및 약학적 조성물 - Google Patents

약학적 조성물의 제조 방법 및 약학적 조성물 Download PDF

Info

Publication number
KR20210032280A
KR20210032280A KR1020200116585A KR20200116585A KR20210032280A KR 20210032280 A KR20210032280 A KR 20210032280A KR 1020200116585 A KR1020200116585 A KR 1020200116585A KR 20200116585 A KR20200116585 A KR 20200116585A KR 20210032280 A KR20210032280 A KR 20210032280A
Authority
KR
South Korea
Prior art keywords
cellulose
range
pharmaceutical
pharmaceutical composition
cnc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020200116585A
Other languages
English (en)
Korean (ko)
Inventor
마르커스 누오포넨
황 샹
하이츄 쑹
유룽 왕
옌신 류
Original Assignee
유피엠-큄메네 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유피엠-큄메네 코퍼레이션 filed Critical 유피엠-큄메네 코퍼레이션
Publication of KR20210032280A publication Critical patent/KR20210032280A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020200116585A 2019-09-13 2020-09-11 약학적 조성물의 제조 방법 및 약학적 조성물 Ceased KR20210032280A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19397527.3 2019-09-13
EP19397527.3A EP3791864A1 (en) 2019-09-13 2019-09-13 Method for preparing pharmaceutical composition and pharmaceutical composition

Publications (1)

Publication Number Publication Date
KR20210032280A true KR20210032280A (ko) 2021-03-24

Family

ID=67997550

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200116585A Ceased KR20210032280A (ko) 2019-09-13 2020-09-11 약학적 조성물의 제조 방법 및 약학적 조성물

Country Status (5)

Country Link
US (1) US11723867B2 (https=)
EP (1) EP3791864A1 (https=)
JP (1) JP7640065B2 (https=)
KR (1) KR20210032280A (https=)
CN (1) CN112494430B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3791858A1 (en) 2019-09-13 2021-03-17 UPM-Kymmene Corporation Injectable pharmaceutical formulation
JP2021090882A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
JP2021090883A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
JP2021090879A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
JP2021090881A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
JP2021090884A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
CN116764001B (zh) * 2023-06-29 2025-11-11 上海交通大学医学院附属第九人民医院 多孔碳基双载药纳米缓释材料及其子宫支架与应用
WO2025155702A1 (en) * 2024-01-19 2025-07-24 University Of Maine System Board Of Trustees Cellulose-based hydrogels as vaccine adjuvants
CN119528842B (zh) * 2024-10-25 2025-12-16 上海工程技术大学 一种通过氧化纳米纤维素调控药物晶型的方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4308336B2 (ja) * 1997-03-14 2009-08-05 株式会社日本吸収体技術研究所 ミクロフィブリル状微細繊維構造体およびその製造方法
AU757605B2 (en) 1999-01-28 2003-02-27 Indevus Pharmaceuticals, Inc. Hydrogel compositions useful for the sustained release of macromolecules and methods of making same
FI20095638A0 (fi) 2009-06-09 2009-06-09 Valtion Teknillinen Hydrofobiineja aktiivisten aineiden dispergointiin
FI123988B (fi) 2010-10-27 2014-01-31 Upm Kymmene Corp Soluviljelymateriaali
FI130619B (en) * 2011-11-15 2023-12-15 Upm Kymmene Corp Matrix for sustained delivery of bioactive agents
BR112015014523A2 (pt) 2012-12-19 2017-07-11 Kashiv Pharma Llc nanossuspensão estabilizada, composição farmacêutica, e, método de tratamento de um paciente
FI126109B (en) 2013-02-22 2016-06-30 Upm Kymmene Corp Nanofibril polysaccharide for use in the control and prevention of constriction and scarring
CN103520739B (zh) 2013-10-22 2015-01-28 东北林业大学 一种纤维素纳米纤丝和吲哚美辛自组装复合体系的制备方法
FI126854B (en) * 2013-12-30 2017-06-30 Upm Kymmene Corp The membrane, its use and the method for making the membrane
JP6712875B2 (ja) 2016-03-04 2020-06-24 第一工業製薬株式会社 繊維芽細胞増殖促進剤
FI3922279T3 (fi) 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
EP3791858A1 (en) 2019-09-13 2021-03-17 UPM-Kymmene Corporation Injectable pharmaceutical formulation

Also Published As

Publication number Publication date
CN112494430A (zh) 2021-03-16
EP3791864A1 (en) 2021-03-17
JP2021046392A (ja) 2021-03-25
CN112494430B (zh) 2023-06-02
JP7640065B2 (ja) 2025-03-05
US20210077403A1 (en) 2021-03-18
US11723867B2 (en) 2023-08-15

Similar Documents

Publication Publication Date Title
US11723867B2 (en) Method for preparing pharmaceutical composition and pharmaceutical composition
Hajiali et al. Mechanochemical transformations of biomass into functional materials
Liu et al. Interactions between cell wall polysaccharides and polyphenols: Effect of molecular internal structure
Yang et al. Carboxymethyl β-cyclodextrin grafted carboxymethyl chitosan hydrogel-based microparticles for oral insulin delivery
Abo-Elseoud et al. Chitosan nanoparticles/cellulose nanocrystals nanocomposites as a carrier system for the controlled release of repaglinide
Rostamabadi et al. Cellulose nanofibers, nanocrystals, and bacterial nanocellulose: Fabrication, characterization, and their most recent applications
Najafi et al. Preparation and characterization of acetylated starch nanoparticles as drug carrier: Ciprofloxacin as a model
JP7069484B2 (ja) 注射可能な医薬製剤
Lin et al. Supramolecular hydrogels from in situ host–guest inclusion between chemically modified cellulose nanocrystals and cyclodextrin
de Jesus Oliveira et al. Microwave-initiated rapid synthesis of phthalated cashew gum for drug delivery systems
Nanda et al. Preparation and characterization of chitosan–polylactide composites blended with Cloisite 30B for control release of the anticancer drug paclitaxel
Kaity et al. Carboxymethylation of locust bean gum: application in interpenetrating polymer network microspheres for controlled drug delivery
Li et al. The use of bacterial cellulose from kombucha to produce curcumin loaded Pickering emulsion with improved stability and antioxidant properties
Wawrzyńczak et al. Metal and metal oxides nanoparticles as nanofillers for biodegradable polymers
Rashki et al. Cellulose-based nanofibril composite materials as a new approach to fight bacterial infections
Dehkhoda et al. Extraction of carboxylated nanocellulose from oat husk: Characterization, surface modification and in vitro evaluation of indomethacin drug release
Hettrich et al. Novel aspects of nanocellulose
Yan et al. Influence of esterification and ultrasound treatment on formation and properties of starch nanoparticles and their impact as a filler on chitosan based films characteristics
Sobhanadhas et al. Topochemical engineering of cellulose-based functional materials
Li et al. Melatonin loaded with bacterial cellulose nanofiber by Pickering-emulsion solvent evaporation for enhanced dissolution and bioavailability
Zheng et al. Fabrication and performance of a spherical cellulose nanocrystal-based hydrophobic drug delivery vehicle using rubber wood
Ciftci et al. Fabrication of polycaprolactone-chitosan/curcumin polymer composite fibers and evaluation of their in vitro release kinetic behavior and antibacterial-antifungal activity
Fahma et al. Production of polyvinyl alcohol–alginate–nanocellulose fibers
Buntum et al. Potential of longan seed extract–loaded alginate–chitosan beads as drug delivery system
Wang et al. Preparation, characterization, and antioxidant activities of cellulose nanocrystals/genistein nanocomposites

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601